Calcified Tissue International

, Volume 86, Issue 5, pp 359–366 | Cite as

Variation in the PTH Gene, Hip Fracture, and Femoral Neck Geometry in Elderly Women

  • M. Tenne
  • F. E. McGuigan
  • H. Ahlborg
  • P. Gerdhem
  • K. ÅkessonEmail author


Parathyroid hormone (PTH) is a principal regulator of calcium homeostasis. Previously, we studied single-nucleotide polymorphisms present in the major genes in the PTH pathway (PTH, PTHrP, PTHR1, PTHR2) in relation to bone mineral density (BMD) and fracture incidence. We found that haplotypes of the PTH gene were associated with fracture risk independent of BMD. In the present study, we evaluated the relationship between PTH haplotypes and femoral neck bone size. Hip structure analysis and BMD of the femoral neck was assessed by DXA in elderly women from the Malmö Osteoporosis Prospective Risk Assessment study. Data on hip fracture, sustained as a result of low trauma, after the age of 45 years were also analyzed. Haplotypes derived from six polymorphisms in the PTH locus were analyzed in 750 women. Carriers of haplotype 9 had lower values for hip geometry parameters cross-sectional moment of inertia (P = 0.029), femoral neck width (P = 0.049), and section modulous (P = 0.06), suggestive of increased fracture risk at the hip. However, this did not translate into an increased incidence of hip fracture in the studied population. Women who suffered a hip fracture compared to those who had not had longer hip axis length (HAL) (P < 0.001). HAL was not significantly different among haplotypes. Polymorphisms in the PTH gene are associated with differences in aspects of femoral neck geometry in elderly women; however, the major predictor of hip fracture in our population was HAL, to which PTH gene variation does not contribute significantly.


Bone architecture/structure Bone density technology Ultrasound Osteoporosis Fracture PTH PTHrP 



Support for the study was received from the Swedish Research Council (grant K2009-53X-14691-07-3), the Greta and Johan Kock Foundation, the A. Påhlsson Foundation, the A. Osterlund Foundation, the Malmö University Hospital Research Foundation, the Research and Development Council of Region Skåne (Sweden), and the Swedish Medical Society. Thanks are also extended to Jan-Åke Nilsson for statistical advice.


  1. 1.
    Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14(Suppl 1):S1–S8CrossRefPubMedGoogle Scholar
  2. 2.
    Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289CrossRefPubMedGoogle Scholar
  3. 3.
    Arden NK et al (1996) The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res 11:530–534CrossRefPubMedGoogle Scholar
  4. 4.
    Koller DL et al (2001) Genome screen for quantitative trait loci underlying normal variation in femoral structure. J Bone Miner Res 16:985–991CrossRefPubMedGoogle Scholar
  5. 5.
    Flicker L et al (1996) Determinants of hip axis length in women aged 10–89 years: a twin study. Bone 18:41–45CrossRefPubMedGoogle Scholar
  6. 6.
    Slemenda CW et al (1996) The genetics of proximal femur geometry, distribution of bone mass and bone mineral density. Osteoporos Int 6:178–182CrossRefPubMedGoogle Scholar
  7. 7.
    Deng FY, Zhao LJ, Pei YF et al (2010) Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in Caucasians. Osteoporos Int 21:579–587CrossRefPubMedGoogle Scholar
  8. 8.
    Howard GM et al (1998) Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: a twin study. J Bone Miner Res 13:1318–1327CrossRefPubMedGoogle Scholar
  9. 9.
    Beamer WG et al (1996) Genetic variability in adult bone density among inbred strains of mice. Bone 18:397–403CrossRefPubMedGoogle Scholar
  10. 10.
    Nordstrom A et al (2004) Interleukin-6 promoter polymorphism is associated with bone quality assessed by calcaneus ultrasound and previous fractures in a cohort of 75-year-old women. Osteoporos Int 15:820–826CrossRefPubMedGoogle Scholar
  11. 11.
    Langdahl BL et al (2003) Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 32:297–310CrossRefPubMedGoogle Scholar
  12. 12.
    Brommage R et al (1999) Daily treatment with human recombinant parathyroid hormone-(1–34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84:3757–3763CrossRefPubMedGoogle Scholar
  13. 13.
    Neer M et al (1993) Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int 3(Suppl 1):204–205CrossRefPubMedGoogle Scholar
  14. 14.
    Hodsman AB et al (2003) Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220CrossRefPubMedGoogle Scholar
  15. 15.
    Chen P et al (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180CrossRefPubMedGoogle Scholar
  16. 16.
    Recker RR et al (2009) Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84. Bone 44:113–119CrossRefPubMedGoogle Scholar
  17. 17.
    Body JJ et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535CrossRefPubMedGoogle Scholar
  18. 18.
    Stroup JS et al (2007) Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Pharmacotherapy 27:779–788CrossRefPubMedGoogle Scholar
  19. 19.
    Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423:332–336CrossRefPubMedGoogle Scholar
  20. 20.
    Stewart AF et al (1980) Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 303:1377–1383PubMedCrossRefGoogle Scholar
  21. 21.
    Tenne M et al (2008) Genetic variation in the PTH pathway and bone phenotypes in elderly women: evaluation of PTH, PTHLH, PTHR1 and PTHR2 genes. Bone 42:719–727CrossRefPubMedGoogle Scholar
  22. 22.
    Gerdhem P et al (2004) Association of the collagen type 1 (COL1A 1) Sp1 binding site polymorphism to femoral neck bone mineral density and wrist fracture in 1044 elderly Swedish women. Calcif Tissue Int 74:264–269CrossRefPubMedGoogle Scholar
  23. 23.
    Gerdhem P et al (2005) Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int 16:1425–1431CrossRefPubMedGoogle Scholar
  24. 24.
    Gerdhem P, Akesson K (2007) Rates of fracture in participants and non-participants in the Osteoporosis Prospective Risk Assessment study. J Bone Joint Surg Br 89:1627–1631CrossRefPubMedGoogle Scholar
  25. 25.
    Gerdhem P et al (2007) Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 22:127–134CrossRefPubMedGoogle Scholar
  26. 26.
    Yoshikawa T et al (1994) Geometric structure of the femoral neck measured using dual-energy X-ray absorptiometry. J Bone Miner Res 9:1053–1064CrossRefPubMedGoogle Scholar
  27. 27.
    Karlsson MK et al (1998) Bone mineral density assessed by quantitative ultrasound and dual energy X-ray absorptiometry. Normative data in Malmo, Sweden. Acta Orthop Scand 69:189–193PubMedGoogle Scholar
  28. 28.
    Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989CrossRefPubMedGoogle Scholar
  29. 29.
    Dong SS et al (2009) Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians. Calcif Tissue Int 85:104–112CrossRefPubMedGoogle Scholar
  30. 30.
    Cho K et al (2008) Polymorphisms in the endothelial nitric oxide synthase gene and bone density/ultrasound and geometry in humans. Bone 42:53–60CrossRefPubMedGoogle Scholar
  31. 31.
    Rivadeneira F et al (2006) Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women. J Bone Miner Res 21:1443–1456CrossRefPubMedGoogle Scholar
  32. 32.
    Moffett SP et al (2005) Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab 90:3491–3497CrossRefPubMedGoogle Scholar
  33. 33.
    Yerges LM et al (2009) Functional characterization of genetic variation in the Frizzled 1 (FZD1) promoter and association with bone phenotypes: more to the LRP5 story? J Bone Miner Res 24:87–96CrossRefPubMedGoogle Scholar
  34. 34.
    Zmuda JM et al (2009) Association analysis of WNT10B with bone mass and structure among individuals of African ancestry. J Bone Miner Res 24:437–447CrossRefPubMedGoogle Scholar
  35. 35.
    Rivadeneira F et al (2004) The influence of an insulin-like growth factor I gene promoter polymorphism on hip bone geometry and the risk of nonvertebral fracture in the elderly: the Rotterdam Study. J Bone Miner Res 19:1280–1290CrossRefPubMedGoogle Scholar
  36. 36.
    Gong G et al (1999) Association of bone dimensions with a parathyroid hormone gene polymorphism in women. Osteoporos Int 9:307–311CrossRefPubMedGoogle Scholar
  37. 37.
    Ahlborg HG et al (2005) Contribution of hip strength indices to hip fracture risk in elderly men and women. J Bone Miner Res 20:1820–1827CrossRefPubMedGoogle Scholar
  38. 38.
    Faulkner KG et al (2006) Femur strength index predicts hip fracture independent of bone density and hip axis length. Osteoporos Int 17:593–599CrossRefPubMedGoogle Scholar
  39. 39.
    Beck TJ (2007) Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5:49–55CrossRefPubMedGoogle Scholar
  40. 40.
    Gregory JS, Aspden RM (2008) Femoral geometry as a risk factor for osteoporotic hip fracture in men and women. Med Eng Phys 30:1275–1286CrossRefPubMedGoogle Scholar
  41. 41.
    Gluer CC et al (1994) Prediction of hip fractures from pelvic radiographs: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 9:671–677CrossRefPubMedGoogle Scholar
  42. 42.
    Duan Y et al (2003) Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 18:1766–1774CrossRefPubMedGoogle Scholar
  43. 43.
    Lei SF et al (2005) The VDR, COL1A1, PTH, and PTHR1 gene polymorphisms are not associated with bone size and height in Chinese nuclear families. J Bone Miner Metab 23:501–505CrossRefPubMedGoogle Scholar
  44. 44.
    Uusi-Rasi K et al (2005) Effects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958CrossRefPubMedGoogle Scholar
  45. 45.
    Parkinson DB, Thakker RV (1992) A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat Genet 1:149–152CrossRefPubMedGoogle Scholar
  46. 46.
    Kilav R, Silver J, Naveh-Many T (2001) A conserved cis-acting element in the parathyroid hormone 3’-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 276:8727–8733CrossRefPubMedGoogle Scholar
  47. 47.
    Kaptoge S et al (2008) Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res 23:1892–1904CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • M. Tenne
    • 1
  • F. E. McGuigan
    • 1
  • H. Ahlborg
    • 1
  • P. Gerdhem
    • 2
    • 3
  • K. Åkesson
    • 1
    • 4
    Email author
  1. 1.Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Science MalmöLund UniversityLundSweden
  2. 2.Department of Clinical Science, Intervention and TechnologyKarolinska InstituteStockholmSweden
  3. 3.Department of OrthopedicsKarolinska University HospitalStockholmSweden
  4. 4.Department of OrthopedicsMalmö University HospitalMalmöSweden

Personalised recommendations